瑞普生物
(300119)
| 流通市值：64.41亿 | | | 总市值：89.37亿 |
| 流通股本：3.35亿 | | | 总股本：4.65亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,544,325,031.33 | 1,707,587,656.8 | 821,616,475.9 | 3,069,933,116.78 |
| 营业收入 | 2,544,325,031.33 | 1,707,587,656.8 | 821,616,475.9 | 3,069,933,116.78 |
| 二、营业总成本 | 2,202,944,319.05 | 1,464,234,653.83 | 694,874,920.33 | 2,690,140,421.73 |
| 营业成本 | 1,475,882,995 | 989,391,177.59 | 482,898,269.73 | 1,799,722,621.6 |
| 税金及附加 | 19,339,952.64 | 13,987,702.16 | 5,832,045.84 | 26,346,455.03 |
| 销售费用 | 366,424,397.96 | 235,038,147.08 | 100,376,582.8 | 451,383,069.54 |
| 管理费用 | 157,658,513.48 | 103,829,285.28 | 49,054,825.1 | 188,944,340.45 |
| 研发费用 | 157,025,388.67 | 104,020,978.37 | 47,940,755.91 | 196,537,745.61 |
| 财务费用 | 26,613,071.3 | 17,967,363.35 | 8,772,440.95 | 27,206,189.5 |
| 其中:利息费用 | 27,216,420.24 | 18,361,731.74 | 9,181,009.35 | 31,214,673.37 |
| 其中:利息收入 | 1,854,734.55 | 1,252,878.73 | 625,210.59 | 4,969,935.23 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 44,482,336.25 | 43,282,384.88 | 25,328,670.23 | -10,707,752.8 |
| 加:投资收益 | 59,907,276.57 | 32,094,818.1 | -701,082.24 | 9,142,829.12 |
| 资产处置收益 | 3,761,700.78 | 3,729,955.17 | 1,061.15 | -16,698.12 |
| 资产减值损失(新) | 373,473.73 | 373,473.73 | 373,473.73 | -19,849,519.54 |
| 信用减值损失(新) | -22,398,851.25 | -20,748,539.02 | -19,476,374.62 | -19,456,021.42 |
| 其他收益 | 14,765,085.85 | 10,040,094.62 | 5,073,106.48 | 34,262,426.62 |
| 四、营业利润 | 442,271,734.21 | 312,125,190.45 | 137,340,410.3 | 373,167,958.91 |
| 加:营业外收入 | 2,123,280.3 | 1,961,830.86 | 221,917.66 | 1,598,005.56 |
| 减:营业外支出 | 3,885,697.25 | 2,577,767.85 | 2,130,159.16 | 6,476,839.56 |
| 五、利润总额 | 440,509,317.26 | 311,509,253.46 | 135,432,168.8 | 368,289,124.91 |
| 减:所得税费用 | 49,717,760.09 | 39,445,666.57 | 15,327,402.5 | 38,455,221.73 |
| 六、净利润 | 390,791,557.17 | 272,063,586.89 | 120,104,766.3 | 329,833,903.18 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 390,791,557.17 | 272,063,586.89 | 120,104,766.3 | 329,833,903.18 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 362,307,052.9 | 256,522,468.88 | 115,984,657.96 | 300,722,269.32 |
| 少数股东损益 | 28,484,504.27 | 15,541,118.01 | 4,120,108.34 | 29,111,633.86 |
| 扣除非经常损益后的净利润 | 269,277,854.2 | 187,741,091.62 | 93,461,027.11 | 280,620,866.2 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.8 | 0.56 | 0.25 | 0.65 |
| (二)稀释每股收益 | 0.8 | 0.56 | 0.25 | 0.65 |
| 九、综合收益总额 | 390,791,557.17 | 272,063,586.89 | 120,104,766.3 | 329,833,903.18 |
| 归属于母公司股东的综合收益总额 | 362,307,052.9 | 256,522,468.88 | 115,984,657.96 | 300,722,269.32 |
| 归属于少数股东的综合收益总额 | 28,484,504.27 | 15,541,118.01 | 4,120,108.34 | 29,111,633.86 |
| 公告日期 | 2025-10-25 | 2025-08-26 | 2025-04-26 | 2025-04-03 |
| 审计意见(境内) | | | | 标准无保留意见 |